How do natural killer T cells help B cells?

Expert Review of Vaccines

Volumn 8, Issue 8, 2009, Pages 1109-1121

  Lang, Mark L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; B lymphocyte; Cognate interaction; NKT cell; Plasma cell

Indexed keywords

CD1D ANTIGEN; RECEPTOR;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL STIMULATION; CELL TYPE; CELLULAR IMMUNITY; DENDRITIC CELL; HELPER CELL; HUMAN; HUMORAL IMMUNITY; MEMORY CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; HUMANS; MICE; NATURAL KILLER T-CELLS;

EID: 68049139189     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.56     Document Type: Review

References (124)

1. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17, 297-329 (1999).
2. Mandal M, Chen XR, Alegre ML et al. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol. Immunol. 35(9), 525-536 (1998).
3. Zimmer MI, Nguyen HP, Wang B et al. Polymorphisms in CD1d affect antigen presentation and the activation of CD1d-restricted T cells. Proc. Natl Acad. Sci. USA 106(6), 1909-1914 (2009).
4. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277(5324), 339-345 (1997).
5. Koch M, Stronge VS, Shepherd D et al. The crystal structure of human CD1d with and without a-galactosylceramide. Nat. Immunol. 6(8), 819-826 (2005).
6. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes. Nat. Rev. 5(5), 387-399 (2005).
7. Zajonc DM, Maricic I, Wu D et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202(11), 1517-1526 (2005).
8. Zajonc DM, Savage PB, Bendelac A, Wilson IA, Teyton L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Va14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J. Mol. Biol. 377(4), 1104-1116 (2008).
9. Zhou D, Mattner J, Cantu C 3rd et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786-1789 (2004).
10. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199(7), 947-957 (2004).
11. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of va14 NKT cells by glycosylceramides. Science 278(5343), 1626-1629 (1997).
12. Kinjo Y, Tupin E, Wu D et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7(9), 978-986 (2006).
13. Wu D, Xing GW, Poles MA et al. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc. Natl Acad. Sci. USA 102(5), 1351-1356 (2005).
14. Mattner J, Debord KL, Ismail N et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434(7032), 525-529 (2005).
15. Natori T, Akimoto K, Motoki K, Koezuka Y, Higa T. Development of KRN7000, derived from agelasphin produced by Okinawan sponge. Nippon Yakurigaku Zasshi - Folia Pharmacologica Japonica 110(Suppl. 1), 63P-68P (1997).
16. Lang GA, Maltsev SD, Besra GS, Lang ML. Presentation of a-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts. Immunology 112(3), 386-396 (2004).
17. Jayawardena-Wolf J, Benlagha K, Chiu YH, Mehr R, Bendelac A. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 15(6), 897-908 (2001).
18. Roberts TJ, Sriram V, Spence PM et al. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J. Immunol. 168(11), 5409-5414 (2002).
19. Cernadas M, Sugita M, van der Wel N et al. Lysosomal localization of murine CD1d mediated by AP-3 is necessary for NK T cell development. J. Immunol. 171(8), 4149-4155 (2003).
20. Lawton AP, Prigozy TI, Brossay L et al. The mouse CD1d cytoplasmic tail mediates CD1d trafficking and antigen presentation by adaptor protein 3-dependent and -independent mechanisms. J. Immunol. 174(6), 3179-3186 (2005).
21. Park YK, Lee JW, Ko YG, Hong S, Park SH. Lipid rafts are required for efficient signal transduction by CD1d. Biochem. Biophys. Res. Comm. 327(4), 1143-1154 (2005).
22. Roy KC, Maricic I, Khurana A, Smith TR, Halder RC, Kumar V. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J. Immunol. 180(5), 2942-2950 (2008).
23. Schrantz N, Sagiv Y, Liu Y, Savage PB, Bendelac A, Teyton L. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. J. Exp. Med. 204(4), 841-852 (2007).
24. Yuan W, Qi X, Tsang P et al. Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc. Natl Acad. Sci. USA 104(13), 5551-5556 (2007).
25. Dougan SK, Salas A, Rava P et al. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J. Exp. Med. 202(4), 529-539 (2005).
26. Gumperz JE. The ins and outs of CD1 molecules: bringing lipids under immunological surveillance. Traffic (Copenhagen, Denmark) 7(1), 2-13 (2006).
27. Burdin N, Brossay L, Koezuka Y et al. Selective ability of mouse CD1 to present glycolipids: a-galactosylceramide specifically stimulates V a 14+ NK T lymphocytes. J. Immunol. 161(7), 3271-3281 (1998).
28. Lang GA, Illarionov PA, Glatman-Freedman A, Besra GS, Lang ML. BCR targeting of biotin-{a}- galactosylceramide leads to enhanced presentation on CD1d and requires transport of BCR to CD1d-containing endocytic compartments. Int. Immunol. 17(7), 899-908 (2005). •• First paper showing B-cell receptor (BCR)-mediated internalization and presentation of CD1d-binding glycolipid antigen (Ag).
29. Prigozy TI, Naidenko O, Qasba P et al. Glycolipid antigen processing for presentation by CD1d molecules. Science 291(5504), 664-667 (2001).
30. van den Elzen P, Garg S, Leon L et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437(7060), 906-910 (2005).
31. Barral P, Eckl-Dorna J, Harwood NE et al. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc. Natl Acad. Sci. USA (2008). •• Demonstrated that BCR capture of CD1d-binding glycolipid Ag led to specific antibody (Ab) responses in vivo.
32. Leadbetter EA, Brigl M, Illarionov P et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc. Natl Acad. Sci. USA (2008). •• Demonstrated that BCR capture of CD1d-binding glycolipid Ag led to specific Ab responses in vivo.
33. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21, 483-513 (2003).
34. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23, 877-900 (2005).
35. Ballas ZK, Rasmussen W. NK1.1+ thymocytes. Adult murine CD4-, CD8- thymocytes contain an NK1.1+, CD3+, CD5hi, CD44hi, TCR-V b8+ subset. J. Immunol. 145(4), 1039-1045 (1990).
36. Matsuda JL, Naidenko OV, Gapin L et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192(5), 741-754 (2000).
37. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 268(5212), 863-865 (1995).
38. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J. Exp. Med. 202(12), 1623-1626 (2005).
39. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol. Today 21(11), 573-583 (2000).
40. Terabe M, Swann J, Ambrosino E et al. A nonclassical non-Va14Ja18 CD1drestricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202(12), 1627-1633 (2005).
41. Wei DG, Lee H, Park SH et al. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J. Exp. Med. 202(2), 239-248 (2005).
42. Griewank K, Borowski C, Rietdijk S et al. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 27(5), 751-762 (2007).
43. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat. Rev. 7(7), 505-518 (2007).
44. Smiley ST, Kaplan MH, Grusby MJ. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science 275(5302), 977-979 (1997).
45. Exley MA, Bigley NJ, Cheng O et al. Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology 110(4), 519-526 (2003).
46. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6(4), 469-477 (1997).
47. Cui J, Shin T, Kawano T et al. Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science 278(5343), 1623-1626 (1997).
48. Chen X, Wang X, Besra GS, Gumperz JE. Modulation of CD1d-restricted NKT cell responses by CD4. J. Leuk. Biol. 82(6), 1455-1465 (2007).
49. Crowe NY, Coquet JM, Berzins SP et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202(9), 1279-1288 (2005).
50. van Der Vliet HJ, Nishi N, de Gruijl TD et al. Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95(7), 2440-2442 (2000).
51. Park SH, Benlagha K, Lee D, Balish E, Bendelac A. Unaltered phenotype, tissue distribution and function of Va14+NKT cells in germ-free mice. Eur. J. Immunol. 30(2), 620-625 (2000).
52. Paul WE. In: Fundamental Immunology (6th Edition). Lippincott Williams and Wilkins, PA, USA (2008).
53. Yoshimoto T, Bendelac A, Hu-Li J, Paul WE. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc. Natl Acad. Sci. USA 92(25), 11931-11934 (1995).
54. Lisbonne M, Diem S, de Castro Keller A et al. Cutting edge: invariant V a 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171(4), 1637-1641 (2003).
55. Yoshimoto T, Min B, Sugimoto T et al. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J. Exp. Med. 197(8), 997-1005 (2003).
56. Akbari O, Stock P, Meyer E et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergeninduced airway hyperreactivity. Nat. Med. 9(5), 582-588 (2003).
57. Campos RA, Szczepanik M, Itakura A et al. Cutaneous immunization rapidly activates liver invariant V{a}14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J. Exp. Med. 198(12), 1785-1796 (2003).
58. Takahashi T, Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur. J. Immunol. 38(1), 156-165 (2008).
59. Schofield L, McConville MJ, Hansen D et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 283(5399), 225-229 (1999).
60. Molano A, Park SH, Chiu YH, Nosseir S, Bendelac A, Tsuji M. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1dindependent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J. Immunol. 164(10), 5005-5009 (2000).
61. Procopio DO, Almeida IC, Torrecilhas AC et al. Glycosylphosphatidylinositolanchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. J. Immunol. 169(7), 3926-3933 (2002).
62. Belperron AA, Dailey CM, Bockenstedt LK. Infection-induced marginal zone B cell production of Borrelia hermsii-specific antibody is impaired in the absence of CD1d. J. Immunol. 174(9), 5681-5686 (2005). • Along with [63], linked natural killer (NK) T cells and CD1dhi marginal zone (MZ) B cells to production of specific Abs that could protect against bacterial pathogens.
63. Kumar H, Belperron A, Barthold SW, Bockenstedt LK. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J. Immunol. 165(9), 4797-4801 (2000). • Along with [62], linked NKT cells and CD1dhi MZ B cells to the production of specific Abs that could protect against bacterial pathogens.
64. Kobrynski LJ, Sousa AO, Nahmias AJ, Lee FK. Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. J. Immunol. 174(4), 1787-1790 (2005).
65. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. a-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175(5), 3309-3317 (2005). •• Shows that a-galactosylceramide can be used as an adjuvant for inducing protective Ab at mucosal surfaces.
66. Lang GA, Exley MA, Lang ML. The CD1d-binding glycolipid a-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1ddependent manner. Immunology 119(1), 116-125 (2006).
67. Devera TS, Shah HB, Lang GA, Lang ML. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur. J. Immunol. 38(4), 1001-1011 (2008). • Demonstrated that NKT activation led to induction of persistent plasma cell responses.
68. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin. Immunol. 20(1), 14-25 (2008).
69. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu. Rev. Immunol. 23, 487-513 (2005).
70. Shinall SM, Gonzalez-Fernandez M, Noelle RJ, Waldschmidt TJ. Identification of murine germinal center B cell subsets defined by the expression of surface isotypes and differentiation antigens. J. Immunol. 164(11), 5729-5738 (2000).
71. McHeyzer-Williams LJ, Cool M, McHeyzer-Williams MG. Antigen-specific B cell memory: expression and replenishment of a novel b220(-) memory B cell compartment. J. Exp. Med. 191(7), 1149-1166 (2000).
72. Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 336(6194), 70-73 (1988).
73. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407(6804), 636-642 (2000).
74. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298(5601), 2199-2202 (2002).
75. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr. Opin Immunol. 18(3), 265-270 (2006).
76. Radbruch A, Muehlinghaus G, Luger EO et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. 6(10), 741-750 (2006).
77. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat. Rev. 5(3), 230-242 (2005).
78. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 8(3), 363-372 (1998).
79. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr. Opin Immunol. 11(2), 172-179 (1999).
80. Noelle RJ, Erickson LD. Determinations of B cell fate in immunity and autoimmunity. Curr. Dir. Autoimmun. 8, 1-24 (2005).
81. Zinkernagel RM. On differences between immunity and immunological memory. Curr. Opin Immunol. 14(4), 523-536 (2002).
82. Benson MJ, Erickson LD, Gleeson MW, Noelle RJ. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr. Opin Immunol. 19(3), 275-280 (2007).
83. Galli G, Pittoni P, Tonti E et al. Invariant NKT cells sustain specific B cell responses and memory. Proc. Natl Acad. Sci. USA 104(10), 3984-3989 (2007). • Demonstrated that Ab recall responses were improved by initial NKT activation.
84. Amano M, Baumgarth N, Dick MD et al. CD1 expression defines subsets of follicular and marginal zone B cells in the spleen: b 2-microglobulin-dependent and independent forms. J. Immunol. 161(4), 1710-1717 (1998).
85. Duan B, Niu H, Xu Z et al. Intrafollicular location of marginal zone/CD1dhi B cells is associated with autoimmune pathology in a mouse model of lupus. Lab. Invest. 88(9), 1008-1020 (2008).
86. Makowska A, Faizunnessa NN, Anderson P, Midtvedt T, Cardell S. CD1high B cells: a population of mixed origin. Eur. J. Immunol. 29(10), 3285-3294 (1999).
87. Bialecki E, Paget C, Fontaine J, Capron M, Trottein F, Faveeuw C. Role of marginal zone B lymphocytes in invariant NKT cell activation. J. Immunol. 182(10), 6105-6113 (2009).
88. Velazquez P, Wei B, McPherson M et al. Villous B cells of the small intestine are specialized for invariant NK T cell dependence. J. Immunol. 180(7), 4629-4638 (2008).
89. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16(2), 219-230 (2002).
90. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28(5), 639-650 (2008).
91. Lang GA, Devera TS, Lang ML. Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood 111(4), 2158-2162 (2008). •• First report that B cell CD1d Ag presentation drives NKT-enhanced Ab responses in vivo.
92. Tonti E, Galli G, Malzone C, Abrignani S, Casorati G, Dellabona P. NKT cell help to B lymphocytes can occur independently of cognate interaction. Blood 113(2), 370-376 (2008).
93. Hermans IF, Silk JD, Gileadi U et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171(10), 5140-5147 (2003).
94. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-g-producing NKT response induced with a-galactosylceramide-loaded DCs. Nat. Immunol. 3(9), 867-874 (2002).
95. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202(2), 203-207 (2005).
96. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198(2), 267-279 (2003).
97. Jung S, Unutmaz D, Wong P et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17(2), 211-220 (2002).
98. Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166(10), 6012-6018 (2001).
99. Williams JA, Lumsden JM, Yu X et al. Regulation of thymic NKT cell development by the B7-CD28 costimulatory pathway. J. Immunol. 181(2), 907-917 (2008).
100. Zheng X, Zhang H, Yin L, Wang CR, Liu Y, Zheng P. Modulation of NKT cell development by B7-CD28 interaction: an expanding horizon for costimulation. PLoS ONE 3(7), e2703 (2008).
101. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand a-galactosylceramide. J. Exp. Med. 198(11), 1631-1641 (2003).
102. Mizuno M, Masumura M, Tomi C et al. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J. Autoimmun. 23(4), 293-300 (2004).
103. Oki S, Tomi C, Yamamura T, Miyake S. Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int. Immunol. 17(12), 1619-1629 (2005).
104. Crowe NY, Uldrich AP, Kyparissoudis K et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 171(8), 4020-4027 (2003).
105. Wilson MT, Johansson C, Olivares-Villagomez D et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl Acad. Sci. USA 100(19), 10913-10918 (2003).
106. Uldrich AP, Crowe NY, Kyparissoudis K et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175(5), 3092-3101 (2005).
107. Parekh VV, Wilson MT, Olivares-Villagomez D et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115(9), 2572-2583 (2005).
108. Chang WS, Kim JY, Kim YJ et al. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 181(10), 6707-6710 (2008).
109. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by a-galactosylceramide. J. Clin. Invest. 115(9), 2328-2329 (2005).
110. Silk JD, Salio M, Reddy BG et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J. Immunol. 180(10), 6452-6456 (2008).
111. Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10(3), 252-258 (1998).
112. Klein U, Kuppers R, Rajewsky K. Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 89(4), 1288-1298 (1997).
113. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188(9), 1679-1689 (1998).
114. van Es JH, Meyling FH, Logtenberg T. High frequency of somatically mutated IgM molecules in the human adult blood B cell repertoire. Eur. J. Immunol. 22(10), 2761-2764 (1992).
115. Weller S, Braun MC, Tan BK et al. Human blood IgM 'memory' B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104(12), 3647-3654 (2004).
116. Kenna T, Golden-Mason L, Porcelli SA et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171(4), 1775-1779 (2003).
117. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(a)24 natural killer T cells. J. Exp. Med. 195(5), 637-641 (2002).
118. Chang DH, Osman K, Connolly J et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201(9), 1503-1517 (2005).
119. Giaccone G, Punt CJ, Ando Y et al. A Phase I study of the natural killer T-cell ligand a-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8(12), 3702-3709 (2002).
120. Ishikawa A, Motohashi S, Ishikawa E et al. A Phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11(5), 1910-1917 (2005).
121. Uchida T, Horiguchi S, Tanaka Y et al. Phase I study of a-galactosylceramidepulsed antigen-presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57(3), 337-345 (2008).
122. Galli G, Nuti S, Tavarini S et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197(8), 1051-1057 (2003).
123. Motohashi S, Ishikawa A, Ishikawa E et al. A Phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12(20 Pt 1), 6079-6086 (2006).
124. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 97(9), 807-812 (2006).